Flumist shipment timing weighs on AZ revenues; DOD hands Profectus $9.5M for Ebola, Marburg trivalent;

> AstraZeneca's ($AZN) U.S. revenue grew 7% in Q3 despite a decline from the timing of FluMist shipments, it said Thursday. Release (PDF)

> Profectus BioSciences has locked down $9.5 million in Department of Defense funding to help it develop a trivalent vaccine for Ebola and Marburg. The cash will support manufacturing and preclinical testing for the vaccine, the company said. Release

> Vaccine-focused contract manufacturing organization Paragon Bioservices has closed a $13 million round of Series A financing. More

> A vaccine candidate that treats opioid abuse could help patients recover from drug addictions. Report

> In a Phase I trial, treatment with Genexine's immunotherapeutic HPV vaccine resulted in viral clearance and complete lesion regression in 7 of 9 treated patients with severe dysplasia or carcinoma in situ. Release

And Finally... A chlamydia vaccine could help save koalas from extinction. More